Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| UK-369,003 | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Effect on exercise tolerance |
| Measure | Description | Time Frame |
|---|---|---|
| Effect on lung function and quality of life |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Córdoba | Córdoba Province | CP 5016 | Argentina | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| San Miguel de Tucumán |
| Pcia de Tucuman |
| 4000 |
| Argentina |
| Pfizer Investigational Site | San Miguel de Tucumán | Pcia de Tucuman | Argentina |
| Pfizer Investigational Site | Rosario | Santa Fé | 2000 | Argentina |
| Pfizer Investigational Site | Buenos Aires | 1272 | Argentina |
| Pfizer Investigational Site | Buenos Aires | 1427 | Argentina |
| Pfizer Investigational Site | Ciudad de Beurnos Aires | C1425DQi | Argentina |
| Pfizer Investigational Site | Ciudad de Buenos Aires, | (C1425DTG) | Argentina |
| Pfizer Investigational Site | Ciudad de Buenos Aires | C1115AAB | Argentina |
| Pfizer Investigational Site | Ciudad de Buenos Aires | C1416DRV | Argentina |
| Pfizer Investigational Site | Provincia de Buenos Aires | (1605) | Argentina |
| Pfizer Investigational Site | Camperdown | New South Wales | 2050 | Australia |
| Pfizer Investigational Site | Darlinghurst | New South Wales | 2010 | Australia |
| Pfizer Investigational Site | Chermside | Queensland | 4032 | Australia |
| Pfizer Investigational Site | Adelaide | South Australia | 5000 | Australia |
| Pfizer Investigational Site | Melbourne | Victoria | 3004 | Australia |
| Pfizer Investigational Site | Perth | Western Australia | 6000 | Australia |
| Pfizer Investigational Site | Giessen | 35392 | Germany |
| Pfizer Investigational Site | Greifestein | 35753 | Germany |
| Pfizer Investigational Site | Kochi | Kerala | 682026 | India |
| Pfizer Investigational Site | Mumbai | Maharashtra | 400016 | India |
| Pfizer Investigational Site | Pune | Maharashtra | 411 019 | India |
| Pfizer Investigational Site | Chennai | Tamil Nadu | 600116 | India |
| Pfizer Investigational Site | Vellore | Tamil Nadu | 632002 | India |
| Pfizer Investigational Site | Papworth Everard | Cambridgeshire | CB3 8RE | United Kingdom |
| Pfizer Investigational Site | Glasgow | G11 6NT | United Kingdom |
| Pfizer Investigational Site | Newcastle upon Tyne | NE7 7DN | United Kingdom |
| Pfizer Investigational Site |
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C553931 | 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine |
Not provided
Not provided
Not provided